Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCARDIA vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Chronic stable angina,Vasospastic angina (Prinzmetal's angina),Hypertension
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
2-5 hours in healthy adults; up to 6-10 hours in cirrhotic patients or elderly; clinical context: requires extended-release formulations for once-daily dosing.
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to inactive metabolites.
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via bile); 0% unchanged in urine.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
92-98% bound to serum albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
1.0-1.5 L/kg; large distribution suggests extensive tissue penetration.
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Immediate-release: 40-60% (extensive first-pass metabolism); sustained-release: 80-90% relative to immediate-release formulation.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
No specific dose adjustment required; use caution in severe renal impairment (GFR <30 m L/min).
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Child-Pugh Class A: reduce dose by 50%; Class B or C: contraindicated or use with extreme caution, reduce dose by 60-75%.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Not FDA-approved for pediatric use; off-label: 0.25-0.5 mg/kg/dose orally every 6-8 hours, maximum 3 mg/kg/day.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Initiate at lower doses (e.g., 10 mg immediate-release 3 times daily or 30 mg XL once daily); titrate slowly; monitor for hypotension and edema.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
No FDA-issued black box warning.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
May cause severe hypotension especially with concomitant beta-blockers,Peripheral edema,Gingival hyperplasia,Hepatic impairment may require dose adjustment,Avoid abrupt discontinuation (may worsen angina),Increased risk of myocardial infarction in patients with coronary artery disease
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Acute myocardial infarction (within first 4 weeks),Concomitant use with strong CYP3A4 inducers or inhibitors
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Grapefruit juice and grapefruit increase the AUC and Cmax of nifedipine by approximately 2-fold due to CYP3A4 inhibition; avoid concurrent consumption. Alcohol may exacerbate hypotension and vasodilatory effects. High-fat meals can delay absorption of extended-release tablets but do not significantly alter overall bioavailability.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second and third trimesters: Associated with reduced uteroplacental blood flow, fetal hypoxia, and low birth weight. Tocolysis use may cause maternal hypotension and fetal distress. Overall, FDA Category C.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Nifedipine is excreted into breast milk; milk-to-plasma ratio approximately 1.0. Low relative infant dose (2-5% of maternal weight-adjusted dose). No reported adverse effects in breastfed infants. However, caution is advised, especially in preterm or low-birth-weight infants. Monitor infant for hypotension or adverse effects.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
No standard dose adjustment required. However, increased clearance and volume of distribution in pregnancy may require dose titration to achieve clinical effect. Start with lowest effective dose.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
Nifedipine (Procardia) is a dihydropyridine calcium channel blocker with potent vasodilatory effects. Avoid sublingual administration of short-acting capsules due to risk of profound hypotension, myocardial ischemia, and stroke. Use only extended-release formulations for chronic hypertension or stable angina. May cause peripheral edema; differentiate from heart failure. Gingival hyperplasia can occur with chronic use. Contraindicated in patients with a history of hypersensitivity to dihydropyridines, cardiogenic shock, significant aortic stenosis, or within 4 weeks of myocardial infarction.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit juice and grapefruit products as they increase nifedipine levels and risk of toxicity.,Report persistent swelling of ankles/feet, severe headaches, dizziness, or palpitations to your healthcare provider.,Rise slowly from sitting or lying positions to minimize orthostatic hypotension.,Practice good oral hygiene and regular dental check-ups to reduce risk of gum overgrowth.,Do not stop taking this medication abruptly; taper under medical supervision to avoid rebound angina.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCARDIA vs CALAN, answered by our medical review team.
PROCARDIA is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCARDIA and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCARDIA is: Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCARDIA and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCARDIA is classified as Category C. First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second an. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.